By Professor Jason Grebely

Journal articles

Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Iser DM; Huang HC; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study', Journal of Virus Eradication, 3, pp. 8 - 8, http://dx.doi.org/10.1016/s2055-6640(20)30904-3

Alavi M; Amin J; Grebely J; Law MG; Janjua NZ; Krajden M; Hajarizadeh B; George J; Matthews GV; Larney S; Degenhardt L; Dore GJ, 2017, 'O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study', Journal of Virus Eradication, 3, pp. 9 - 9, http://dx.doi.org/10.1016/s2055-6640(20)30906-7

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study', Journal of Virus Eradication, 3, pp. 2 - 3, http://dx.doi.org/10.1016/s2055-6640(20)30889-x

Iversen J; Grebely J; Catlett B; Cunningham P; Dore GD; Maher L, 2017, 'O9 Progress towards elimination: rapid uptake of HCV treatment among people who inject drugs following broad access to DAA therapies', Journal of Virus Eradication, 3, pp. 4 - 4, http://dx.doi.org/10.1016/s2055-6640(20)30892-x

Cunningham E; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Hajarizadeh B; Dore GJ; Lloyd A; Grebely J, 2017, 'P10 Injecting risk behaviours among people who inject drugs in an Australian prison setting, 2005–2014: the HITS-p study', Journal of Virus Eradication, 3, pp. 15 - 16, http://dx.doi.org/10.1016/s2055-6640(20)30751-2

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia', Journal of Virus Eradication, 3, pp. 19 - 19, http://dx.doi.org/10.1016/s2055-6640(20)30761-5

Bajis S; Lamoury F; Applegate TL; Maher L; Treloar C; Mowat Y; Schulz M; Hajarizadeh B; Marshall A; Cunningham E; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Dore GJ; Grebely J, 2017, 'P4 Acceptability of point of care finger-stick and venepuncture hepatitis C virus testing among people who inject drugs and homeless people', Journal of Virus Eradication, 3, pp. 13 - 14, http://dx.doi.org/10.1016/s2055-6640(20)30745-7

Bartlett SR; Applegate T; Jacka B; Lamoury F; Bull R; Danta M; Bradshaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2017, 'P6 Phylogenetic clustering of recent hepatitis C virus infection between 2004 and 2015', Journal of Virus Eradication, 3, pp. 14 - 15, http://dx.doi.org/10.1016/s2055-6640(20)30747-0

Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', Journal of Hepatology, 66, pp. S513 - S514, http://dx.doi.org/10.1016/s0168-8278(17)31429-0

Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials', Clinical Infectious Diseases, 63, pp. 1405 - 1411, http://dx.doi.org/10.1093/cid/ciw580

Grebely J; Dore GJ; Zeuzem S; Aspinall RJ; Fox R; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Natha M; Foster GR; Mangia A; Sulkowski M; Feld JJ, 2016, 'Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials', Clinical Infectious Diseases, 63, pp. 1479 - 1481, http://dx.doi.org/10.1093/cid/ciw579

Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176

Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV; Cooper D, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844

Tsui JI; Mirzazadeh A; Hahn JA; Maher L; Bruneau J; Grebely J; Hellard M; Kim AY; Shoukry NH; Cox AL; Prins M; Dore GJ; Lauer G; Lloyd AR; Page K, 2016, 'The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males', Drug and Alcohol Dependence, 169, pp. 156 - 162, http://dx.doi.org/10.1016/j.drugalcdep.2016.10.024

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ; Han A, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010

Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AYM; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL, 2016, 'Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial', Annals of Internal Medicine, 165, pp. 625 - 634, http://dx.doi.org/10.7326/M16-0816

Rodrigo C; Eltahla AA; Bull RA; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Estes C; Razavi H; Lloyd AR; Luciani F, 2016, 'Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia', Journal of Infectious Diseases, 214, pp. 1383 - 1389, http://dx.doi.org/10.1093/infdis/jiw389

Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ; Han A, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025

Janjua NZ; Kuo M; Yu A; Alvarez M; Wong S; Cook D; Wong J; Grebely J; Butt ZA; Samji H; Ramji A; Tyndall M; Krajden M, 2016, 'The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC)', EBioMedicine, 12, pp. 189 - 195, http://dx.doi.org/10.1016/j.ebiom.2016.08.035

Thabet K; Asimakopoulos A; Shojaei M; Romero-Gomez M; Mangia A; Irving WL; Berg T; Dore GJ; Grønbæk H; Sheridan D; Abate ML; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Spengler U; Nattermann J; Wahid A; Rojas A; White R; Douglas MW; McLeod D; Powell E; Liddle C; Van Der Poorten D; George J; Eslam M; Gallego-Duran R; Applegate T; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C', Nature Communications, 7, pp. 12757, http://dx.doi.org/10.1038/ncomms12757

Grebely J; Litwin A; Dore GJ, 2016, 'Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all', Journal of Viral Hepatitis, 23, pp. 664 - 666, http://dx.doi.org/10.1111/jvh.12550

Montoya V; Olmstead A; Tang P; Cook D; Janjua N; Grebely J; Jacka B; Poon AFY; Krajden M, 2016, 'Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing', Infection, Genetics and Evolution, 43, pp. 329 - 337, http://dx.doi.org/10.1016/j.meegid.2016.06.015

Eslam M; Mangia A; Berg T; Chan HLY; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MAM; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J; White R; Rojas A; Gallego-Duran R; Bassendine M; Wong VWS; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes', Hepatology, 64, pp. 34 - 46, http://dx.doi.org/10.1002/hep.28475

Martin NK; Vickerman P; Dore GJ; Grebely J; Miners A; Cairns J; Foster GR; Hutchinson SJ; Goldberg DJ; Martin TCS; Ramsay M; Hickman M, 2016, 'Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation', Journal of Hepatology, 65, pp. 17 - 25, http://dx.doi.org/10.1016/j.jhep.2016.02.007

Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J; Dolan K, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, 16, pp. 241, http://dx.doi.org/10.1186/s12879-016-1567-2

Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; Kaldor J; Marks P; Lloyd A; Haber P; French R; White P; Rawlinson W; Day C; Van Beek I; McCaughan G; Madden A; Dolan K; Farrell G; Crofts N; Sievert W; Baker D, 2016, 'Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort', PLoS ONE, 11, pp. e0150655, http://dx.doi.org/10.1371/journal.pone.0150655

Bourgeois S; Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Sulkowski M; Feld JJ; Carr V; Liu L; Ding X; McNally J; Osinusi A; Brainard DM; Subramanian M, 2016, 'SOF/VEL for 12 weeks is well tolerated and results in high SVR12 rates in people receiving opioid substitution therapy', HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 18, pp. 16 - 16

Jacka B; Applegate T; Poon AF; Raghwani J; Harrigan PR; Debeck K; Milloy MJ; Krajden M; Olmstead A; Joy JB; Marshall BDL; Hayashi K; Pybus OG; Lima VD; Magiorkinis G; Montaner J; Lamoury F; Dore GJ; Wood E; Grebely J, 2016, 'Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada', Journal of Hepatology, 64, pp. 1247 - 1255, http://dx.doi.org/10.1016/j.jhep.2016.02.031

MacParland SA; Fadel SM; Mihajlovic V; Fawaz A; Kim C; Nur-Ur Rahman AKM; Liu J; Kaul R; Kovacs C; Grebely J; Dore GJ; Wong DK; Ostrowski MA, 2016, 'HCV specific IL-21 producing T cells but not IL-17A producing T cells are associated with HCV viral control in HIV/HCV coinfection', PLoS ONE, 11, pp. e0154433, http://dx.doi.org/10.1371/journal.pone.0154433

Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, 13, pp. 32, http://dx.doi.org/10.1186/s12985-016-0482-x

Grebely J; Dore GJ; Greenwald R; Swan T; Barua S; Taylor LE, 2016, 'Hepatitis c virus treatment and persons who inject drugs', Annals of Internal Medicine, 164, pp. 203, http://dx.doi.org/10.7326/L15-0485

Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ, 2016, 'Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study', Addiction, 111, pp. 311 - 319, http://dx.doi.org/10.1111/add.13197

Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9

Sagan SM; Dupont B; Grebely J; Krajden M; Macparland SA; Raven JF; Saeed S; Feld JJ; Tyrrell DL; Wilson JA, 2016, 'Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan', Canadian Journal of Gastroenterology and Hepatology, 2016, pp. 5743521, http://dx.doi.org/10.1155/2016/5743521

Bartlett SR; Jacka B; Bull RA; Luciani F; Matthews GV; Lamoury FMJ; Hellard ME; Hajarizadeh B; Teutsch S; White B; Maher L; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection', Infection, Genetics and Evolution, 37, pp. 252 - 258, http://dx.doi.org/10.1016/j.meegid.2015.11.028

Page K; Mirzazadeh A; Rice TM; Grebely J; Kim AY; Cox AL; Morris MD; Hellard M; Bruneau J; Shoukry NH; Dore GJ; Maher L; Lloyd AR; Lauer G; Prins M; McGovern BH, 2016, 'Interferon lambda 4 genotype is associated with jaundice and elevated aminotransferase levels during acute hepatitis C virus infection: Findings from the InC3 collaborative', Open Forum Infectious Diseases, 3, pp. ofw024, http://dx.doi.org/10.1093/ofid/ofw024

Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', ANTIVIRAL THERAPY, 21, pp. 425 - 434, http://dx.doi.org/10.3851/IMP3035

Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', Antiviral therapy, 21, pp. 465, http://dx.doi.org/10.3851/IMP3073

Van Buuren N; Fradette L; Grebely J; King A; Krajden M; Macparland SA; Marshall A; Saeed S; Wilson J; Klein MB; Sagan SM, 2016, 'The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet - Remaining Challenges in Hepatitis C', Canadian Journal of Gastroenterology and Hepatology, 2016, pp. 7603526, http://dx.doi.org/10.1155/2016/7603526

Grebely J; Flamm S; Zeuzem S; Hyland R; Chang P; Ding X; Yun C; Brainard D; McHutchison J; Forns X; Mangia A; Dore G, 2016, 'On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study', Journal of Hepatology, 64, pp. S776 - S777, http://dx.doi.org/10.1016/s0168-8278(16)01514-2

Gastroenterology CAO; For The Study Of The Liver CA, 2016, 'Program and Abstracts from the Canadian Digestive Diseases Week™ 2016.', Can J Gastroenterol Hepatol, 2016, pp. 4792898, http://dx.doi.org/10.1155/2016/4792898

Marshall AD; Saeed S; Barrett L; Cooper CL; Treloar C; Bruneau J; Feld JJ; Gallagher L; Klein MB; Krajden M; Shoukry NH; Taylor LE; Grebely J; Canadian Network on Hepatitis C (CanHepC) , 2016, 'Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.', CMAJ Open, 4, pp. E605 - E614, http://dx.doi.org/10.9778/cmajo.20160008

Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Liu L; Ding X; McNally J; Osinusi A; Brainard D; Subramanian M; Sulkowski M; Feld J, 2016, 'SOF/VEL for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy', Journal of Hepatology, 64, pp. S776 - S776, http://dx.doi.org/10.1016/s0168-8278(16)01513-0

Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JSG, 2015, 'Are interferon-free direct-acting antivirals for the treatment of HCV enough to control the epidemic among people who inject drugs?', PLoS ONE, 10, pp. e0143836, http://dx.doi.org/10.1371/journal.pone.0143836

Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Spelman T; Matthews G; Rice TM; Morris MD; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns MP; Hellard ME; Dore GJ; Maher L, 2015, 'Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort', Journal of Viral Hepatitis, 22, pp. 1020 - 1032, http://dx.doi.org/10.1111/jvh.12429

Alavi M; Micallef M; Fortier E; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J, 2015, 'Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study', Journal of Viral Hepatitis, 22, pp. 914 - 925, http://dx.doi.org/10.1111/jvh.12415

Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY; Mcgovern BH; Shoukry NH; Schinkel J; Allen TM; Morris M; Hajarizadeh B; Maher L; Lloyd AR; Page K; Hellard M; Matthews G, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC³ study', Journal of Infectious Diseases, 212, pp. 1407 - 1419, http://dx.doi.org/10.1093/infdis/jiv220

Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs', International Journal of Drug Policy, 26, pp. 1039 - 1040, http://dx.doi.org/10.1016/j.drugpo.2015.07.008

Fortier E; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Bruneau J; Grebely J, 2015, 'The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study', International Journal of Drug Policy, 26, pp. 1094 - 1102, http://dx.doi.org/10.1016/j.drugpo.2015.06.001

Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A; Haber P; Carolyn D; Gregory D; Tawil V; Krahn M; Loveday S; Thein HH, 2015, 'Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia', International Journal of Drug Policy, 26, pp. 999 - 1006, http://dx.doi.org/10.1016/j.drugpo.2015.07.006

Back to profile page